Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 6/20 | 0.51 |
| ▸ | PDE2A | O00408 | 4/20 | 0.44 |
| ▸ | POLQ | O75417 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6681467 | 1.00 | CES2 (0.51) | CES2PDE2APOLQKDM4ECES1 | |
| SCHEMBL6681459 | 1.00 | CES2 (0.51) | CES2PDE2APOLQKDM4ECES1 | |
| SCHEMBL6679457 | 0.86 | CES2 (0.51) | CES2PDE2APOLQKDM4ECES1 | |
| SCHEMBL6679460 | 0.86 | CES2 (0.51) | CES2PDE2APOLQKDM4ECES1 | |
| SCHEMBL6701810 | 0.86 | CES2 (0.51) | CES2PDE2APOLQKDM4ECES1 | |
| SCHEMBL6676167 | 0.83 | PDE2A (0.47) | CES2PDE2AKDM4ECES1ALDH1A1 | |
| SCHEMBL7473523 | 0.83 | CES2 (0.42) | CES2CES1 | |
| SCHEMBL7473531 | 0.83 | CES2 (0.42) | CES2CES1 | |
| SCHEMBL8974847 | 0.83 | PDE2A (0.60) | CES2PDE2AKDM4ECES1ALDH1A1 | |
| SCHEMBL8974843 | 0.83 | PDE2A (0.60) | CES2PDE2AKDM4ECES1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040249220-A1 | Process for producing optically active 2-alkoxy-1-(trifluoromethyl-substituted phenyl) ethanol derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249220-A1 | Process for producing optically active 2-alkoxy-1-(trifluoromethyl-substituted phenyl) ethanol derivatives | ADH1A, ADH1C, ADH5 | CES2 115/4885PDE2A 3242/4885POLQ 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.